Abénex Capital to carve out InLog from Haemonetics

The transaction is expected to close in this quarter and is subject to customary conditions.

As part of the deal, Haemonetics will sell its France-based subsidiary to the GP, including the EdgeSuite software package, which includes EdgeBlood, EdgeCell, EdgeTrack, EdgeLab and SapaNet.

The deal will help Haemonetics shift its portfolio towards growth segments. The company generated revenues of $988m in its last financial year.  

Abénex has recently been investing from its fifth flagship fund, Abénex V, which reached a final close on €425m in December 2017. The mid-market buyout fund invests €15-60m in companies with enterprise values of €50-300m. 

Company
Founded in 2008 and headquartered in Limonest, InLog develops and sells blood bank and hospital software. 

People
Abénex Capital – Thomas Peretti (director). 
Haemonetics – Chris Simon (president, CEO). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• France
• Technology
• France
• healthcare
• Mid-market buyout